Lilly beats estimates as injectable GLP-1 demand widens gap with Novo
Reuters reports resilient demand for Lilly's injectable incretin drugs drove the quarterly beat as the company pulls further ahead of its Danish rival.
MH
By Maren Holt · Senior Reporter, GLP-1
Aug 5 03:00 ETSource: Reuters
The wire
- 01Eli Lilly beat analyst estimates on the back of demand for its injectable GLP-1 medicines, according to Reuters.
- 02Lilly's widening lead over Novo Nordisk shapes pricing, supply and formulary dynamics that clinicians and telehealth operators face on incretin prescribing.
- 03Only the headline summary is available here; specific revenue figures, guidance and segment detail were not in the text provided.
From the source
Read at reuters.comLilly beats estimates on resilient demand for injectable GLP-1 drugs, widens gap with Novo